Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6548556 | 1.00 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL4756623 | 1.00 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL20038792 | 0.97 | — | — | |
| SCHEMBL16792336 | 0.91 | — | — | |
| SCHEMBL1337717 | 0.84 | — | — | |
| SCHEMBL13169085 | 0.82 | TP53 (0.39) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL20354169 | 0.82 | KDM4E (0.42) | TP53KDM4E | |
| SCHEMBL10843765 | 0.79 | KDM4E (0.37) | TP53KDM4ELMNA | |
| SCHEMBL5981075 | 0.78 | TP53 (0.36) | TP53KDM4EGMNNLMNAMAPT | |
| SCHEMBL8137257 | 0.78 | TP53 (0.36) | TP53KDM4EGMNNLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122627-B2 | Lactam inhibitors of Hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040171556-A1 | Methods for inhibiting proteasome | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-02 | — | — | US | disclosed |
| WO-2004064755-A2 | METHODS FOR INHIBITING PROTEASOME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-05 | — | — | WO | disclosed |
| US-6586615-B1 | Boron compounds such as 1-amino-3,3-difluoropropyl boronate pinacol ester used as intermediates for antagonists of serine proteases, leukocyte elastases, cathepsins, chymotrypsin and hepatitis virus enzyme inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-01 | — | — | US | disclosed |
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-09 | — | — | US | disclosed |
| WO-2002054931-A2 | ALPHA-AMINOBORONIC ACIDS PREPARED BY NOVEL SYNTHETIC METHODS | BRISTOL MYERS SQUIBB COMPANY P (US) | 2002-07-18 | — | — | WO | disclosed |
| EP-1206449-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-05-22 | — | — | EP | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001007407-A1 | LACTAM INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008828-A1 | Diagnostic kits; for therapy of viral infection; as assat standard or reagent | PRSS3, PRSS1, PREP | TP53 2252/4885KDM4E 4253/4885GMNN 2631/4885 |
| US-20040171556-A1 | Methods for inhibiting proteasome | PSMB1, PSMB11, PSMG3 | TP53 376/4885KDM4E 1782/4885GMNN 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.